Acute kidney injury

Acute kidney injury (AKI) is a rapid deterioration in kidney function — occurring over hours to days — in which the kidneys lose the ability to filter waste products from the blood and regulate fluid balance. Blood levels of creatinine and urea rise; urine output often falls.

In drug-related harm, AKI almost always arrives as a downstream consequence of something else. Rhabdomyolysis — the breakdown of skeletal muscle that releases myoglobin into the bloodstream — is the most common upstream cause in stimulant and MDMA-related harms, where sustained heat, physical exertion, and cardiovascular strain converge.

Prolonged immobility during an overdose can trigger the same process. Severe dehydration, circulatory collapse, and sustained hyperthermia each restrict blood flow to the kidneys independently. Some substance classes also carry direct toxicity to kidney tissue. Any of these pathways can arrive together.

How it is done

AKI is recognised by a pattern of signs rather than a single one. A marked drop in urine output — or urine that has turned dark brown or tea-coloured from myoglobin — is often the most visible early indicator. Generalised fatigue, nausea, lower back pain, and swelling in the legs or face may follow as waste accumulates in the blood.

Clinical identification requires blood tests. Creatinine and blood urea nitrogen are the primary markers, and only those values can establish whether AKI is present, how severe it is, and whether the trend is stabilising or worsening.

Harm reduction practices address the conditions that precede AKI rather than AKI itself. Preventing prolonged hyperthermia, maintaining hydration at a steady pace, and limiting time in immobile positions each reduce the likelihood that the upstream cascade reaches the kidneys.

When it matters

AKI becomes urgent when urine output stops or approaches zero, when confusion or extreme fatigue develops alongside other signs of drug toxicity, or when the circumstances — sustained overheating, a long period of immobility, a known stimulant or opioid overdose — suggest kidney stress is likely even before symptoms surface.

At that point, the duration of the injury begins to determine whether function recovers fully or leaves lasting impairment. Emergency assessment provides the blood markers needed to track the kidneys' trajectory and, if needed, arrange dialysis support. The window between the onset of the upstream conditions and the point of irreversible damage is not reliably reflected in how a person feels.

What it cannot tell you

The warning signs of AKI can be absent or arrive late. Dark urine reflects myoglobin that has already accumulated; its absence does not rule out ongoing muscle breakdown. Someone under significant kidney stress may feel only vaguely unwell, or not unwell at all.

Feeling better is not the same as recovery. A period of subjective improvement can follow even while blood markers remain abnormal — a window during which the kidneys remain vulnerable to additional strain. Only repeat blood testing confirms that function has returned to baseline.

AKI does not reveal its own cause. The upstream pathway — rhabdomyolysis, direct nephrotoxicity, blood-flow failure — carries different treatment implications, and identifying AKI begins that investigation rather than closing it.